Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia

ABSTRACT: Although chronic urticaria (CU) is a common, cause of medical consulting both in general practitioners and allergist specialists worldwide, there is little information about its behavior and management in Latin America. Currently, national and international guidelines recommend using Omali...

Full description

Autores:
Sánchez Caraballo, Jorge Mario
García Gómez, Elizabeth
Chapman, Edgardo
García Paba, María Beatriz
Ocampo Gómez, Jaime
Egea Bermejo, Eduardo
Garavito De Egea, Gloria
Fang, Luis
Sarrazola, Mauricio
Serrano Reyes, Carlos
Silva Espinosa, Diana Lucia
Rojas Mejía, Dolly Vanessa
Moreno López, Sergio Mauricio
Tipo de recurso:
Article of investigation
Fecha de publicación:
2022
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/38003
Acceso en línea:
https://hdl.handle.net/10495/38003
Palabra clave:
Urticaria
Angioedema
Antagonistas de los Receptores Histamínicos
Histamine Antagonists
Omalizumab
Antihistamínicos
Antihistamines
https://id.nlm.nih.gov/mesh/D014581
https://id.nlm.nih.gov/mesh/D000799
https://id.nlm.nih.gov/mesh/D006633
https://id.nlm.nih.gov/mesh/D000069444
Rights
openAccess
License
https://creativecommons.org/licenses/by/4.0/
Description
Summary:ABSTRACT: Although chronic urticaria (CU) is a common, cause of medical consulting both in general practitioners and allergist specialists worldwide, there is little information about its behavior and management in Latin America. Currently, national and international guidelines recommend using Omalizumab for cases refractory to management with antihistamines. Despite advances in the knowledge of Omalizumab for the management of CU, although there are few studies in underdeveloped countries, there are many studies evaluating the impact of Omalizumab treatment. There is not clinical information related with CSU-Omalizumab in patient settled in the Caribbean area. This research aims to evaluate the management of CU with Omalizumab in a real-life scenario in Colombia.